Policy Decisions on Endocrine Disruptors Should Be Based on Science Across Disciplines: A Response to Dietrich et al.


Division of Pharmacology and Toxicology, The University of Texas, Austin, Texas 78712 (A.C.G.); University of Liège, GIGA Neurosciences, B-4000 Liège, Belgium (J.B.); VA Medical Center and University of California, San Francisco, San Francisco, California 94143 (D.B.); Institute for Health and the Environment, University at Albany, State University of New York, Albany, New York 12222 (D.O.C.); Section of Integrative Biology, The University of Texas, Austin, Texas 78712 (D.C.); Professor Emeritus of Pediatrics, University of Paris, 75006 Paris, France (P.C.); Medical School University of Athens, Sotiria Hospital, Athens 115 27, Greece (E.D.-K.); Department of Biological Sciences, University of Denver, Denver, Colorado 80208 (R.M.D.); Department of Anatomy, University of Otago, North Dunedin 9016, New Zealand (D.G.); Icahn School of Medicine at Mt Sinai, New York, New York 10029 (P.R.H.); Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02115 (A.N.H.); University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota 55455 (C.L.); University of Pittsburgh Cancer Institute and Magee Women’s Research Institute, Pittsburgh, Pennsylvania 15213 (A.V.L.); Wisconsin National Primate Research Center, Madison, Wisconsin 53715 (J.E.L.); UCT/MRC Receptor Biology Unit, University of Cape Town, Cape Town, South Africa (R.P.M.); Department of Neuroscience, The Ohio State University Wexner Medical Center, Columbus, Ohio 43210 (R.J.N.); Hospital del Mar Institute of Medical Research and School of Medicine, Universitat Autònoma de Barcelona, 080041 Barcelona, Spain (M.Porta); Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 (M.Poth); Department of Biosciences, Universidade do Algarve, 8005–139 Faro, Portugal (D.M.P.); Department of Physiology and Biophysics, University of Illinois, Chicago, Illinois 60612 (G.S.P.); Department of Medicine, University of Colorado School of Medicine, Denver, Colorado 80208 (E.C.R.); Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, Virginia 22908 (E.F.R.); Division of Medicine, Academic Medical Center, University of Amsterdam, 1012 WX Amsterdam, The Netherlands (J.A.R.); Laboratory of Neuronal Structure and Function, The Salk Institute, La Jolla, California 92037 (P.E.S.); Queensland Children’s Medical Institute, University of Queensland, Royal Children’s Hospital, Brisbane, Queensland 4000, Australia (P.D.S.); Karolinska Institutet at Karolinska University Hospital Solna, 171 76 Stockholm, Sweden (O.S.); Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut 06510 (H.S.T.); Department of Cell Biology and Physiology, University of Córdoba, 14071 Córdoba, Spain (M.T.-S.); Institut National de la Santé et de la Recherche Médicale U982, University of Rouen, 76821 Rouen, France (H.V.); Department of Psychology and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30322 (K.W.); Department of Psychology and Neuroscience, Florida State University, Tallahassee, Florida 32306 (Z.W.); Department of Medicine, Washington Hospital Center, Washington, DC 20010; and Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77555 (C.S.W.)
W e are writing as scientists and editors of leading peer-reviewed journals that have published important contributions in the study of endocrine disrupting chemicals (EDCs). By signing this editorial, we affirm that regulatory decisions on EDCs should be made based on the best available science and expertise that involves, among others, reproductive biology, endocrinology, medicine, genetics, behavior, developmental biology, and toxicology (1). (For a complete list of Signatories and their Disclosures, see Supplemental Table 1 published on The Endocrine Society’s Journals Online web site at http://end.endojournals.org.)

Thousands of published studies have revealed the health effects of EDCs on wildlife and laboratory animals and, moreover, have shown associations of EDCs with effects in humans. Many of these studies have been reviewed recently by The Endocrine Society, the United Nations Environment Programme (UNEP) and World Health Organization (WHO), and other independent scientists (2–5). The conclusions presented in each of these documents are extraordinarily consistent: like hormones, EDCs are active at very low doses and can induce a range of adverse health outcomes, many of which are not examined in traditional toxicology assays (1). In sum, these reports point to the conclusion that EDCs pose a global health threat.

A recent editorial signed by a number of editors of toxicology journals argues for the status quo in the regulation of EDCs (6), despite the large volume of evidence indicating that current regulations are ineffective in protecting human populations from these chemicals (4–7). As the UNEP/WHO report notes, the incidence of chronic disease among people from these chemicals (4–7). As the UNEP/WHO report notes, the incidence of chronic disease is now greater than that of communicable disease; many of these diseases have an endocrine basis. Both experimental animal and epidemiology studies provide plausible causal links between EDCs and many of these diseases; for some, the data are sufficiently robust (8).

The dismissive approach to endocrine disruption science put forth by Dietrich et al (6) is unfounded, as it is neither based on the fundamental principles of how the endocrine system works and how chemicals can interfere with its normal function, nor does it consider the consequences of that interference. Their letter also ignores a growing and rigorous body of literature on both endogenous hormonal and exogenous EDC effects.

Basic scientists, clinical investigators, and physicians understand that the endocrine system’s functions and responses change remarkably across the life cycle. Of particular concern is incontrovertible evidence, published more than a half century ago (9, 10), that there are critical life stages, especially during early development, when hormones dictate the differentiation and development of tissues. Any perturbation of the delicate hormonal balance, whether due to the absence of natural hormones or the presence of exogenous hormones, can have irreversible effects on endocrine-sensitive organs. EDCs are known to upset this delicate balance.

Dietrich et al (6) also misrepresent the state of science on thresholds, stating that the evidence “clearly demonstrates the presence of a threshold for nongenotoxic compounds including EDCs.” Dietrich et al assert that their position constitutes “common sense” and that the European Commission’s approach departs from common sense. They do not, however, provide scientific support for this position. Instead, they list several references (11–15) that, upon examination, do not contain data supporting their assumption but rather simply assert that the assumption is true. They also fail to address the considerable literature that speaks against that assumption (eg, Refs 16–20). Finally, they argue that structuring regulation upon the assumption of no threshold “will set an unforeseen precedent [sic].” This is simply and demonstrably not true. The assumption of no threshold has been widely used, for many years, in the regulation of genotoxic carcinogens, often based on in vitro data. We believe extending this precedent to EDCs is supported by the science (19).

Furthermore, we hold that common sense dictates that policies, particularly those in which public health is at stake, should be based on scientific evidence obtained from the world’s leading researchers and should derive from a more evolved, modern understanding of the science, rather than on older, outdated concepts and data taught in classrooms 20 or more years ago. The European Commission policy, by that standard, does represent “common sense.”

Further, the US National Academy of Sciences has concluded that because of the range of susceptibility to environmental chemicals across the population, such as that from age, preexisting conditions, and genetic variation, and because there are documented exposures to multiple chemicals, including EDCs, in the population, it is more appropriate to consider lack of thresholds at a population level (16).

Many toxicologists have developed rigorous research programs on EDCs that incorporate endocrinological principles, including two former presidents of the Society of Toxicology, Cheryl Walker and Linda Birnbaum. They and many other toxicologists do work in this area and report results that have contributed to the breadth and depth of concern about EDCs as a global public health threat. The ad hominem attacks in Dietrich et al (6) do nothing to advance science or opportunities to protect public health; we refer readers to two additional responses to their editorial that support this point of view (21, 22).

We need the fields of toxicology, endocrinology and other stakeholders to work together to address these issues, not engage in recriminations.
Policymakers in Europe and elsewhere should base their decisions on science, not on assumptions based on principles that arose out of research on chemicals that are not EDCs. The letter by Dietrich et al does the European Commission, science, including the field of toxicology, and most importantly, public health, a profound disservice.

Acknowledgments
The following is the list of signatories. The complete list of their affiliations and disclosure information is provided in Supplemental Table 1.

Signatories
Journal Editors-in-Chief:
1. Prof. Jacques Balthazart, PhD, Frontiers in Neuroendocrinology
2. David O. Carpenter, MD, Reviews on Environmental Health
3. Paul Czernichow, MD, Hormone Research in Pediatrics
4. Donald B. DeFranco, PhD, Molecular Endocrinology
5. Robert M. Dores, PhD, General and Comparative Endocrinology
6. Andrea C. Gore, PhD, Endocrinology
7. David Grattan, PhD, Journal of Neuroendocrinology
8. Stephen R. Hammes, MD, PhD, Editor-in-Chief elect, Molecular Endocrinology
9. Patrick R. Hof, MD, Journal of Comparative Neurology
10. Carol Lange, PhD, Hormones and Cancer
11. Jon E. Levine, PhD, Frontiers in Neuroendocrinology
12. Deborah M. Power, PhD, General and Comparative Endocrinology
13. Professor Robert P. Millar, PhD, FRSE, Neuroendocrinology
14. E. Chester Ridgway, MD, MACP, Endocrine Reviews
15. Johannes A. Romijn, MD, PhD, European Journal of Endocrinology
16. Peter D. Sly, MBBS, FRACP, MD, DSc, Reviews on Environmental Health
17. Hubert Vaudry, PhD, DrSci, Frontiers in Neuroendocrine Science; also Senior Editor, Journal of Neuroendocrinology; Associate Editor, Hormone and Metabolic Research; Associate Editor, General and Comparative Endocrinology; Associate Editor, Peptides
18. Kim Wallen, PhD, Hormones and Behavior
20. Cheryl S. Watson, PhD, Endocrine Disruptors

Journal Associate Editors
1. Åke Bergman, PhD, Archives of Environmental Contamination and Toxicology; Environmental Science and Pollution Research
2. Daniel Bickle, MD, PhD, Endocrinology
3. Barbara A. Cohn, PhD, Endocrine Disruptors
4. David Crews, PhD, Endocrine Disruptors; Journal of Experimental Zoology; Ecological Genetics and Physiology; Sexual Development; Epigenetics
5. Peter L. DeFur, PhD, Endocrine Disruptors
6. Eavanthia Diamanti-Kandarakis, MD, PhD, European Journal of Endocrinology
7. Anthony N. Hollenberg, MD, Endocrinology
8. Susan Jobling, PhD, Endocrine Disruptors
9. Jun Kanno, MD, PhD, Environmental Health Perspectives
10. Carolyn Klinge, PhD, Endocrine Disruptors
11. B. Paige Lawrence, PhD, Endocrine Disruptors
12. Adrian V. Lee, PhD, Endocrinology
13. J. P. Myers, PhD, Endocrine Disruptors
14. Randy J. Nelson, PhD, Hormones and Behavior
15. Miquel Porta, MD, MPH, PhD, Journal of Epidemiology & Community Health; European Journal of Clinical Investigation; European Journal of Epidemiology
17. Gail S. Prins, PhD, Endocrinology, Andrology
18. Emilie F. Rissman, PhD, Endocrinology
19. Paul E. Sawchenko, PhD, Journal of Comparative Neurology
20. Olle Söder, MD, PhD, Hormone Research in Pediatrics
21. Ana M. Soto, MD, Progress in Biophysics and Molecular Biology
22. Shanna Swan, PhD, Endocrine Disruptors
23. Hugh S. Taylor, MD, Endocrinology
24. Manuel Tena-Sempere, MD, PhD, Endocrinology
25. Frederick vom Saal, PhD, Endocrine Disruptors
26. Zuoxin Wang, PhD, Hormones and Behavior
27. Wade V. Welschons, PhD, Endocrine Disruptors
28. R. Thomas Zoeller, PhD, Endocrine Disruptors

Additional Signatories
1. Benson T. Akingbemi, PhD
2. Koji Arizono, PhD
3. Scott M. Belcher, PhD
4. Fiorella Belpoggi, PhD
5. Carl-Gustaf Bornehag, PhD
6. Jean-Pierre Bourguignon, MD, PhD
7. Terry J. Collins, PhD
8. Ernesto Burgio, MD
9. Terrence J. Collins, PhD
10. D. Andrew Crain, PhD
11. Barbara Demeneix, PhD
12. Rodney R. Dietert, PhD
13. Loretta Doan, PhD
14. Randy J. Nelson, PhD, Hormones and Behavior
15. Mariana F. Fernandez, PhD
16. Thea M. Edwards, PhD
17. R. William Field, PhD, MS
18. Linda C. Giudice, MD, PhD
19. Louis J. Guillette, PhD
20. Y. Leon Guo, MD, PhD, MPH
References


